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The facilitatory effect of duloxetine combined with pelvic floor
muscle training on the excitability of urethral sphincter motor
neurons
Abstract
INTRODUCTION AND HYPOTHESIS: Aim of this study was to investigate the excitability of
sphincter motor neurons under the influence of pelvic floor muscle training (PFMT) and duloxetine.
Due to their mechanisms of action, there might be a synergistic effect of duloxetine and PFMT in regard
to the facilitation of spinal reflexes controlling urethral sphincter contractions and hence continence.
METHODS: In ten healthy female subjects, clitoral electric stimulation (CES) and transcranial magnetic
stimulation (TMS) were used to determine individual motor thresholds for external urethral sphincter
(EUS) contractions before and after PFMT, duloxetine, and PFMT + duloxetine. RESULTS: PFMT and
duloxetine alone significantly decreased the motor thresholds for EUS contractions during CES and
TMS. However, the combined treatment reduced the motor threshold for EUS contractions significantly
stronger compared to PFMT or duloxetine alone. CONCLUSIONS: The results are suggestive for a
synergistic facilitatory effect of PFMT and duloxetine on sphincter motor neuron activation.
The facilitatory effect of duloxetine combined with pelvic floor muscle training 
on the excitability of urethral sphincter motor neurons. 
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Abstract: 
 
Introduction and Hypothesis: 
Aim of this study was to investigate the excitability of sphincter motor neurons under the 
influence of pelvic floor muscle training (PFMT) and duloxetine. Due to their mechanisms of 
action there might be a synergistic effect of duloxetine and PFMT in regard to the facilitation 
of spinal reflexes controlling urethral sphincter contractions and hence continence. 
 
Methods: 
In 10 healthy female subjects clitoral electric stimulation (CLES) and transcranial magnetic 
stimulation (TCMS) were used to determine individual motor thresholds for external urethral 
sphincter (EUS) contractions before and after PFMT, duloxetine, and PFMT + duloxetine. 
 
Results: 
PFMT and duloxetine alone significantly decreased the motor thresholds for EUS 
contractions during CLES and TCMS. However, the combined treatment reduced the motor 
threshold for EUS contractions significantly stronger compared to PFMT or duloxetine alone. 
 
Conclusions: 
The results are suggestive for a synergistic facilitatory effect of PFMT and duloxetine on 
sphincter motor neuron activation. 
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Keywords: 5HT/NE reuptake inhibitors, duloxetine, external urethral sphincter, motor 
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Summary: Duloxetine combined with pelvic floor muscle training seems to have a 
significant synergistic effect decreasing urethral sphincter motor thresholds during 
transcranial magnetic and bulbocavernousus reflex stimulation. 
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Introduction 
Stress urinary incontinence (SUI) – defined as the complaint of involuntary leakage on effort 
or exertion, or on sneezing or coughing [1] - is an often bothersome symptom that reduces the 
quality of life (QoL), including sexual health [1, 2]. SUI occurs when bladder pressure 
exceeds urethral closure pressure under conditions of increased abdominal pressure. The peak 
incidence of SUI occurs between 45 and 49 years of age and obesity, pregnancy, and vaginal 
childbirth are recognized risk factors [2]. The prevalence of SUI is about 50% among women 
with urinary incontinence (UI) [3]. UI in women is a common disorder and the median 
worldwide prevalence is indicated with 27.6% and is considered even higher in institutional 
settings [4]. 
Different factors can have an influence on the pathogenesis of SUI [5] and several theories 
exist regarding the underlying mechanism or dysfunction causing SUI, including urethral 
hypermobility and intrinsic sphincter deficiency [6, 7], the “backboard” or “hammock” 
concept [8] and the integral theory [9]. Accordingly, there are different treatment options 
correcting the assumed cause of SUI, including different urethral sling surgeries, 
colposuspension, urethral bulking agents, vaginal pessaries, and pelvic floor muscle training 
(PFMT). 
Drug treatment for SUI played only a subordinate role until duloxetine, a combined serotonin 
and norepinephrine reuptake inhibitor, was introduced in the treatment of SUI a few years ago 
and showed promising results [10]. Its main mechanism of action in SUI treatment is to 
increase the tone of the external urethral sphincter by increased availability of the excitatory 
neurotransmitters serotonin and norepinephrine in the sacral spinal cord, where the sphincter 
motoneurons are located [11-13]. 
Although PFMT, a recommended first line therapy for SUI, and duloxetine, as a first drug of 
its class used in SUI, are shown to be effective conservative treatment options, little is known 
about a combined effect of both therapies.   
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Up to day there is only one randomized controlled clinical trial investigating the combined 
treatment of PFMT and duloxetine in women with SUI [14]. The results suggested an additive 
effect of a combined treatment. The aim of this study was now, based on previous experience 
and findings [11], to explore a possible working mechanism and reason for the potential 
benefit of the combined therapy, using neurophysiological and urodynamical measurements. 
Our hypothesis is that duloxetine in combination with PFMT has a synergistic effect on the 
excitability of pudendal motor neurons, more than duloxetine or PFMT alone. 
 
 
Subjects and Methods 
After approval of the local ethics committee (Kantonale Ethikkommission Zürich), a 
volunteer sample of healthy females was recruited. Inclusion criteria: healthy female, age 18 
to 30 years. Exclusion criteria: urinary tract infection, pregnancy, previous child birth, any 
current health problem or medication, any past or current lower urinary tract disorder and any 
allergy to duloxetine. All subjects were informed in written and oral form and had to provide 
written informed consent prior to inclusion. 
Urinary tract infection and pregnancy were excluded prior to the investigation, using urine dip 
stick tests. 
Before starting the experiment, PFMT was explained to the subjects in detail and correct 
contraction was assessed by intravaginal manual control, requiring a maximal contraction 
around the finger and a slight inward lift, without straining and contraction of the abdominal 
muscles or lifting the whole pelvis due to contraction of the buttocks. The PFMT instruction, 
the exercises itself and all other measurements during the experiment were performed with 
subjects in supine position. 
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The experiment consisted of 4 measurements, during which the individual resting motor 
threshold for external urethral sphincter (EUS) contraction in response to clitoral electric 
stimulation (CLES) and transcranial magnetic stimulation (TCMS) was determined (Fig. 1). 
Prior to measurement 1, a 8 Fr Microtip catheter (Unitip, Unisensor AG, Attikon, 
Switzerland) was inserted transurethraly and the bladder was filled by 100 ml. The urethral 
pressure transducer of the catheter was placed at the point of maximum urethral pressure and 
fixated properly with tape on the inside of the left thigh. Additionally, a vaginal probe 
(Periform intravaginal probe, Neen, Oldham, UK) with a length of 8 cm was placed. The 
position of both, the catheter and the vaginal probe was assessed prior to each measurement or 
PFMT using fluoroscopy (Fig. 2). 
CLES was performed using a bipolar stimulator (AS100, ALEA Solutions GmbH, Zürich, 
Switzerland), which was connected to two surface disc electrodes beside the clitoris. The 
current was slowly increased until a contraction response could be observed from the pressure 
transducer at the EUS. 
TCMS was performed using a liquid cooled magnetic coil (MC125, Dantec Medical A/S, 
Skovlunde, Denmark) connected to a magnetic stimulator (MagPro, Dantec Medical A/S, 
Skovlunde, Denmark) with a maximum magnetic field strength of 1.8 Tesla. During 
stimulation, the coil was positioned in midline over the cranial motor cortex and after 
determination of the area of best response (hot spot), the magnetic field strength was slowly 
increased until a contraction response could be observed from the pressure transducer at the 
EUS. CLES and TCMS were repeated alternately twice per measurement, to exclude a mutual 
effect and to assess reproducibility. 
Between measurement 1 and 2, and 3 and 4, PFMT was performed for 10 minutes with a 
contraction frequency of 0.5 Hz under biofeedback monitoring (AutoMove AM800 by 
Danmeter A/S, Odense, Denmark) with 1 minute of training alternating with 1 minute of rest 
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(Fig. 1). All subjects were requested to perform maximum pelvic floor muscle contractions 
during the training, which was controlled via the biofeedback display. 
Between measurement 2 and 3, subjects received 40 mg of duloxetine (Cymbalta®, Eli Lilly 
SA, Vernier/Genève, Switzerland) and had a 4 hour rest, during which the catheter and 
vaginal probe were removed. After measurement 2 and 4, uroflowmetry and measurement of 
post void residual volume was performed. 
The mean of the two thresholds determined with CLES and TCMS during each measurement 
were compared between the individual measurements using the Wilcoxon signed ranks test in 
SPSS 14.0 (SPSS Inc. Headquarters, 233 S. Wacker Drive, 11th floor, Chicago, Illinois 
60606). Due to multiple comparisons, α was corrected to 0.016 (Bonferroni method). 
 
 
Results 
Ten healthy female subjects (age: 24.5 ±2.9 years) could be included (Table 1). The 
experimental procedure was well tolerated and all subjects completed the study. Side effects 
were limited to nausea in two and tiredness in four subjects. None of the subjects indicated 
pain during catheterisation, magnetic stimulation or electrical clitoris stimulation. 
Individual motor thresholds for EUS contraction could be obtained in response to CLES and 
TCMS during all 4 measurements in all subjects (Table 1).   
 
Effect of PFMT on the excitability of EUS neurons (measurement 1 vs. 2) 
After PFMT, the individual motor thresholds for EUS contractions during CLES and TCMS 
were significantly lower (Fig. 3, 4). 
 
Effect of duloxetine on the excitability of EUS neurons (measurement 1 vs. 3) 
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4 hours after duloxetine intake, the individual motor thresholds for EUS contractions during 
CLES and TCMS were significantly lower (Fig. 3, 4). 
 
Combined effect of duloxetine and PFMT on the excitability of EUS neurons (measurement 2 
vs. 4 and 3 vs. 4) 
After combined treatment with duloxetine and PFMT, the individual motor thresholds for 
EUS contractions during CLES and TCMS were even significantly lower compared to PFMT 
or duloxetine alone (Fig. 3, 4). 
 
 
Discussion 
According to our hypothesis, duloxetine and PFMT combined significantly reduced the motor 
thresholds for EUS contractions even more compared to duloxetine or PFMT alone. 
PFMT in the treatment of SUI can presumably work via three different ways: a) conscious 
pelvic floor muscle pre-contraction during physical stress, b) strength training, or/and c) 
indirect training of the pelvic floor muscles via abdominal muscle training [15]. An optimal 
outcome of PFMT for SUI patients would be to reach the automatic (unconscious) co-
contraction level, which is present in healthy continent subjects. How this result can be 
obtained best, whether with option a), b), c) or in combination is still unclear [15]. The 
evidence for the efficacy of indirect training via abdominal muscles (option c) is however 
poor. To date there is only one study comparing PFMT with PFMT + transversus abdominus 
training, finding no benefit of adding transversus abdominus training [16]. 
Regarding the facilitatory neuromodulative effects of muscle training, it could be 
demonstrated in several studies that even short-term muscle training increases the excitability 
in supraspinal and also in spinal centres [17, 18]. This is one of the first mechanisms together 
with adaptations in motor unit recruitment which is involved in the very early changes after 
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starting muscle training [18]. The supraspinal regions involved in EUS control and 
coordination of pelvic floor muscles including the EUS have been revealed in several imaging 
studies using PET and fMRI [19]. As our findings demonstrate, PFMT not only decreases the 
motor threshold during TCMS but also during CLES, which is in principle nothing else than 
bulbocavernosus reflex testing. This would possibly implicate that PFMT not only cause 
changes in supraspinal regions but also in the sacral spinal cord in regard of facilitating sacral 
viscero-somatic reflexes. 
PFMT is yet the first line therapy for SUI, mixed urinary incontinence and sometimes even 
urgency urinary incontinence and based on the available data, it seems that PFMT is better 
than no treatment, placebo, or inactive control treatments [20]. Short term cure rates with 
PFMT are encouraging with rates of 44-70% (≤2 g of urine leak on pad test), although no 
consensus exists regarding a gold standard measure for cure [15]. 
It can take however up to 4 to 8 weeks to improve strength and/or timing of PFM contractions 
and as long as 5 months to show a clinical improvement in SUI for the patients [15, 21]. 
Therefore, the efficacy and long term results of PFMT, next to a skilled training education by 
a specialised physiotherapist, very much relies on the motivation and compliance of the 
patient. Compliance and motivation is even more important as PFMT should be continued 
indefinitely following a certain standardised regimen [22]. 
Although most studies on long term follow up are difficult to compare due to differences in 
training regiment, outcome measures and long term compliance with PFMT, the results of 
some studies show that in the majority of patients a beneficial effect of PFMT can be 
maintained and that the patients do not require surgery anymore. However, there is still a need 
for a large randomized placebo-controlled long-term study on the clinical effectiveness and 
quality of life, which is in addition sufficient for subgroup analysis [20]. 
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Regarding the cost effectiveness, PFMT with a ratio of €0.03/incontinence episode (IE) 
avoided, is favourable over duloxetine with a ratio of  €3.81/IE (the underlying calculations 
refer to the Netherlands. The results can not necessarily applied to other countries) [23]. 
Duloxetine is a first pharmacological therapy option for SUI. It can not completely cure SUI 
and 40 mg bid used for SUI treatment can cause several adverse events (most commonly: 
nausea, vomiting, constipation, headache, dry mouth, fatigue, dizziness and insomnia) 
appearing in 1-25% of patients receiving duloxetine in trials, which resulted in 
discontinuation of the drug in about 1 of 8 people [10]. Although it is approved in several 
european countries since August 2004 for the treatment of SUI, it is not approved by the 
United States Food and Drug Administration (FDA) due to safety concerns (www.fda.gov).  
Nevertheless, it could be shown in several randomised controlled trials, that duloxetine is 
superior to placebo and can significantly reduce incontinence and improve QoL [10]. It has a 
relatively balanced combined inhibitory effect on the synaptic reuptake of serotonin (5-
Hydroxytryptamin, 5-HT) and norepinephrine (NE). Although α-adrenoceptors and 5-HT 
receptors can be found throughout the human body and with high density in several areas in 
the spinal cord, there is a specific high receptor density in the sacral ventral horns of the 
spinal cord, in the area of the Onuf nucleus, where the urethral sphincter motoneurons are 
located [13]. Thor and Katofiasc could demonstrate in their study with anaesthetized cats, that 
duloxetine was able to decrease bladder contractions and increase bladder capacity. This 
effect was even more pronounced in cat bladders, treated with acetic acid. Additionally, 
duloxetine showed an increase in muscle activity of the EUS [13]. Both effects, on bladder 
capacity and sphincter activity increased dose dependently. However, systemic administration 
of duloxetine did not result in inhibition or decrease of bladder contraction evoked by direct 
stimulation of the pelvic nerve, which suggests an effect of duloxetine rather in the central 
nervous system than peripheral. Further studies in cats revealed that the receptors 5-HT2 and 
α1 mediate the facilitation of pudendal nerve reflexes [24, 25]. A study in humans emphasised 
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this conclusion in regard to the α1-receptor, showing a decrease in rhabdosphincter 
electromyography activity after administration of the α1-adrenergic receptor antagonist 
prazosin, indicating that endogenous NE was being tonically released to maintain urethral 
motor neuron activity via the activation of α1-adrenoceptors [26]. Another study in humans 
affirmed the results from the cat studies and found a significant increased contractibility of the 
EUS towards sacral magnetic stimulation after administration of duloxetine [11]. The results 
of a recent study with a sneeze-induced incontinence model in rats demonstrated that 
duloxetine can prevent SUI by facilitating noradrenergic and serotonergic systems in the 
spinal cord to enhance the sneeze-induced urethral closure mechanism [27]. Furthermore, the 
results suggested that EUS continence reflexes during sneezing are likely to be regulated by a 
complex balance among facilitatory 5-HT-receptors, α1- adrenoceptors and inhibitory α2-
adrenoceptors [27]. 
That duloxetine probably has an effect on the human sacral spinal cord, could be 
demonstrated in this study by a reduced threshold for EUS contractions to TCMS and CLES. 
This finding is in accordance with previous studies and suggests a facilitatory effect of 
duloxetine on pudendal sphincter motor neurons in humans [11, 13]. How far there is an 
effect of duloxetine on supraspinal centres regulating EUS and pelvic floor muscles remains 
however unclear. 
 
Regarding the hitherto known mechanism of action of duloxetine and PFMT in SUI, it can be 
assumed that a combination of both will show a synergistic effect in regard to the motor 
neuron excitability of the EUS. Bearing in mind the hypothesis, that reaching an automatic 
activation level of the pelvic floor and EUS could be an essential component to regain 
continence [15], this combined treatment with a significant reduction of the excitability 
threshold might be a reasonable way to facilitate autonomic reflex contractions in women 
with SUI. Furthermore, duloxetine taken in course, rather than continously, might improve 
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compliance with PFMT at the beginning, when PFMT takes some time to show an effect and 
during relapse [28]. Similar studies as described above in animal models are lacking in 
humans, but those few neurophysiological investigations in humans performed hitherto are 
the first steps towards a better understanding of the improved continence with duloxetine 
found in the past clinical trials. It remains however, a mandatory future challenge to further 
explore the exact mechanism of action of duloxetine on the human LUT and to validate a 
combined regimen of PFMT and duloxetine in clinical practice. 
 
There are some limitations of the study. First limitation is the use of healthy subjects without 
SUI, which restricts the translation of our results on women with SUI.  
A second limitation is the small sample size of 10 subjects, which were investigated in a non 
placebo-controlled non-randomized study. However, this study was planned as a proof of 
principle study and based on these findings, randomised placebo controlled clinical trials on 
patients with SUI and age matched healthy subjects are a necessary next step. Our intention 
was to show the possible mechanism behind a combined treatment of PFMT and duloxetine, 
which was demonstrated as beneficial in a randomized placebo controlled trial by Ghoniem et 
al. [14].  
A third limitation is that we cannot completely exclude an influence of the first PFMT on M3 
and M4. Although we cannot prove that the effect of the first PFMT has been washed out 
before M3, we would expect at least a similar threshold as after the first PFMT or probably a 
slight return to baseline. We would not expect a further decrease, as also clinical 
effects/benefits of PFMT does not further improve on its own without further training. If 
training is stopped, the effect of the training starts to return to baseline. We therefore attribute 
the further decrease to duloxetine. One might now argue that the measurements itself might 
caused a reduction in motor thresholds. That however is highly unlikely as corticomotor 
threshold determination using single pulse TCMS is a reproducible method with reliable 
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outcome [29] and we did not observe any influence on the thresholds by the TCMS or CLES 
itself in pretests, which we performed before the initiation of the study. A facilitation of 
cortical excitability and modulation of the corticomotor threshold can occur, if repeated 
TCMS is used for several minutes, whereas low frequency stimulation (1 Hz) suppresses 
cortical excitability and high frequent stimulation (> 5Hz) increases cortical excitability. 
Single impulses used for threshold determination however did not show any influence on 
cortical excitability [30].  Regarding CLES, determination of the bulbocavernosus reflex 
threshold just 2 times during one measurement and with at least 15 minutes interval between 
measurements, we would not expect any facilitation.  
A forth limitation is that neither CLES nor TCMS reflect of course a physiological 
stimulation and cannot be compared to or resemble a guarding pelvic floor contraction in 
daily life. However, CLES and TCMS in combination with a pressure transducer in the EUS 
are standardized, objective, minimally invasive and very reproducible measures of neuronal 
excitability in regard to sphincter contractions and therefore useful to investigate therapeutic 
influences on the efferent pathway of the EUS. If these electrophysiologically measured 
changes in our study population have a relevant impact on the daily life SUI in affected 
women has to be further determined in randomized clinical trials. 
 
 
 
 
Conclusion 
Despite some limitations, the results of this functional study of the female lower urinary tract 
under the influence of PFMT, duloxetine, and PFMT with duloxetine combined, suggest that 
the combined treatment causes the lowest excitability thresholds for EUS contractions during 
CLES and TCMS in young healthy females. Although PFMT and duloxetine alone 
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significantly lowered the excitability threshold, the best effect could be obtained with the 
combination of both, which might be a possible explanation for the synergistic mechanism of 
action of the combined treatment. Reduced excitability thresholds might help to promote 
continence by amplifying and /or accelerating the EUS reflex contractions during abdominal 
stress. Although results from this basic study cannot be readily translated to a patient 
population with SUI, a combined treatment might be worth to be further investigated in 
patients, in whom PFMT alone is not sufficient enough or who show difficulties with training 
compliance do to the prolonged onset of effect of the PFMT. 
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Tables 
 
 
Table 1: Subject characteristics and raw data of all threshold measurements (TCMS & CLES). 
The grey highlighted numbers indicate the mean values of the two TCMS and CLES 
threshold determinations in each measurement, which were used for the statistical calculation. 
M = measurement, SD = standard deviation, BMI = body mass index.  
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Figure legends 
 
 
 
Fig. 1: Experimental paradigm and timing. M = measurement, PFMT = pelvic floor muscle 
training, EUS = external urethral sphincter, CLES = clitoral electric stimulation, TCMS = 
transcranial magnetic stimulation. 
 
 
 
Fig. 2: Fluoroscopy image of one subject, showing the vaginal probe and the transurethral 
catheter with pressure transducers intravesical and at the external urethral sphincter. 
 
 
 
 
Fig. 3: Motor thresholds for external urethral sphincter (EUS) contractions during clitoral 
electric stimulation (CLES). The boxplots show minimum, 25% percentile, median, 75% 
percentile and maximum. Braces indicate significance level between the four different 
measurements. 
 
 
 
 
Fig. 4: Motor thresholds for external urethral sphincter (EUS) contractions during transcranial 
magnetic stimulation (TCMS). The boxplots show minimum, 25% percentile, median, 75% 
percentile and maximum. Braces indicate significance level between the four different 
measurements. 
 
  Subjects   
M Parameter 1 2 3 4 5 6 7 8 9 10 Mean SD 
 Age [years] 21 25 29 23 29 25 26 23 21 23 24.5 2.9 
 BMI [kg/cm2] 20 19 22 22 22 20 21 23 21 20 21 1.2 
 Obstetric status nulli-parous 
nulli-
parous 
nulli-
parous 
nulli-
parous 
nulli-
parous 
nulli-
parous 
nulli-
parous 
nulli-
parous 
nulli-
parous 
nulli-
parous   
 Occupation student student student student student student student student student student   
 Physical activity level None of the subjects was performing physical training more than once a week or was professionally involved in sport activities.   
1 EUS motor threshold CLES 1 28 20 30 10 25 26 27 38 24 20 24.8 7.3 
 EUS motor threshold CLES 2 27 20 30 11 22 26 27 38 24 20 24.5 7.1 
 Mean of 1 & 2 27.5 20 30 10.5 23.5 26 27 38 24 20 24.7 7.2 
 EUS motor threshold TCMS 1 96 89 99 84 88 80 67 83 79 87 85.2 9.0 
 EUS motor threshold TCMS 2 99 86 91 82 86 80 67 83 75 79 82.8 8.7 
 Mean of 1 & 2 97.5 87.5 95 83 87 80 67 83 77 83 84.0 8.7 
2 EUS motor threshold CLES 1 21 18 27 10 23 15 25 35 22 13 20.9 7.3 
 EUS motor threshold CLES 2 22 15 27 10 25 16 25 35 24 13 21.2 7.6 
 Mean of 1 & 2 21.5 16.5 27 10 24 15.5 25 35 23 13 21.1 7.4 
 EUS motor threshold TCMS 1 95 80 94 79 86 73 64 83 75 80 80.9 9.4 
 EUS motor threshold TCMS 2 95 80 93 76 86 74 63 83 71 76 79.7 9.9 
 Mean of 1 & 2 95 80 93.5 77.5 86 73.5 63.5 83 73 78 80.3 9.6 
3 EUS motor threshold CLES 1 20 15 19 10 22 16 22 22 21 19 18.6 3.9 
 EUS motor threshold CLES 2 27 14 20 10 18 16 20 20 21 17 18.3 4.5 
 Mean of 1 & 2 23.5 14.5 19.5 10 20 16 21 21 21 18 18.5 4.0 
 EUS motor threshold TCMS 1 90 82 93 74 83 65 66 82 72 71 77.8 9.7 
 EUS motor threshold TCMS 2 90 80 90 73 81 63 61 82 72 71 76.3 10.1 
 Mean of 1 & 2 90 81 91.5 73.5 82 64 63.5 82 72 71 77.1 9.8 
4 EUS motor threshold CLES 1 22 10 18 8 18 14 22 17 20 13 16.2 4.8 
 EUS motor threshold CLES 2 21 9 19 8 15 14 21 18 20 13 15.8 4.8 
 Mean of 1 & 2 21.5 9.5 18.5 8 16.5 14 21.5 17.5 20 13 16.0 4.8 
 EUS motor threshold TCMS 1 83 78 86 72 81 60 58 83 61 65 72.7 10.9 
 EUS motor threshold TCMS 2 80 75 82 69 79 58 55 79 60 65 70.2 10.1 
 Mean of 1 & 2 81.5 76.5 84 70.5 80 59 56.5 81 60.5 65 71.5 10.5 
 




